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Vanessa Quenehen, Thi Thu Trang Mai, Pierre Deprez, Roland Blanque,́ Line Oste, Sandrine Le Tallec,
Steve De Vos, Annick Hagers, Ann Vandevelde, Luc Nelles, Nele Vandervoort, Katja Conrath,
Thierry Christophe, Ellen van der Aar, Emanuelle Wakselman, Didier Merciris, Ceĺine Cottereaux,
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ABSTRACT: GPR84 is a medium chain free fatty acid-binding G-protein-coupled receptor associated with inflammatory and
fibrotic diseases. As the only reported antagonist of GPR84 (PBI-4050) that displays relatively low potency and selectivity, a clear
need exists for an improved modulator. Structural optimization of GPR84 antagonist hit 1, identified through high-throughput
screening, led to the identification of potent and selective GPR84 inhibitor GLPG1205 (36). Compared with the initial hit, 36
showed improved potency in a guanosine 5′-O-[γ-thio]triphosphate assay, exhibited metabolic stability, and lacked activity against
phosphodiesterase-4. This novel pharmacological tool allowed investigation of the therapeutic potential of GPR84 inhibition. At
once-daily doses of 3 and 10 mg/kg, GLPG1205 reduced disease activity index score and neutrophil infiltration in a mouse dextran
sodium sulfate-induced chronic inflammatory bowel disease model, with efficacy similar to positive-control compound sulfasalazine.
The drug discovery steps leading to GLPG1205 identification, currently under phase II clinical investigation, are described herein.
■ INTRODUCTION
GPR84 is a G-protein-coupled receptor (GPCR) that couples
almost exclusively to pertussis-toxin sensitive Gi/o pathways.
1
Whereas GPR84 has no unanimously accepted cognate ligand,
medium-chain free fatty acids (MCFAs, carbon chain lengths
of 9−14) have been known as agonists for over a decade1,2
with decanoic acid (C10), undecanoic acid (C11), and lauric
acid (C12) being the most effective.3 An increasing range of
synthetic GPR84 agonist ligands have been described,
including embelin, 3,3′-diindolylmethane (DIM), 6-n-octyla-
minouracil (6-OAU),3 and 2-(hexylthiol)pyrimidine-4,6 diol
(2-HTP)4,5 (Figure 1). These synthetic GPR84 ligands are
more potent than the MCFAs, with particular derivatives and
structural relatives of 6-OAU being the most potent agonists of
GPR84 to date.4−6
GPR84 is primarily expressed in innate immune cells
(neutrophils,1,7 monocytes,1 macrophages,1,8 dendritic cells,9
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and microglia8,10) and splenic T and B cells.11 Expression of
GPR84 is highly upregulated by inflammatory stimuli in these
innate immune cells and adipocytes,12 suggesting an
immunoregulatory role for the receptor.1,7,10−13 In polymor-
phonuclear leukocytes and macrophages, activation of GPR84
results in chemotactic responses and enhances the release of
cytokines (interleukin [IL]-8, IL-12, and tumor necrosis factor
α [TNF-α]).1,3 In addition, activation of this receptor in
neutrophils and macrophages triggers the release of reactive
oxygen species.14
GPR84 is suspected to be involved in inflammatory bowel
disease (IBD), as increased levels of GPR84 messenger RNA
(mRNA) have been observed in intestinal mucosal biopsies of
patients with IBD (either ulcerative colitis or Crohn’s
disease).15 Additionally, GPR84 may be involved in fibrotic
processes, as one recent study observed that GPR84 knock-out
mice display significantly reduced kidney fibrosis when
compared with wild-type mice in an adenine-induced chronic
kidney disease model.16 Moreover, in a mouse bleomycin-
induced pulmonary fibrosis model, treatment with the
nonspecific GPR84 antagonist PBI-4050 reduced histological
lesions in the lung by 47% compared with vehicle.16 Other
animal disease models have indicated a role for GPR84 in
chronic pain,3 reflux esophagitis,17 acute myeloid leukemia,18
obesity,19 and Alzheimer’s disease.9 As such, GPR84 has
emerged as a potential drug target, particularly for inflamma-
tory and fibrotic diseases.
To date, only one low potency, nonspecific antagonist of
GPR84 has been reported (PBI-4050), which inhibits GPR84
Gα/i activation initiated by either sodium decanoate or
embelin.16 In this article, we describe the discovery of
GLPG1205 (36), a potent and selective GPR84 modulator,
which demonstrates efficacy in in vivo IBD models and has
been progressed in phase IIa clinical trials for the treatment of
ulcerative colitis.
■ RESULTS AND DISCUSSION
During the course of our investigations, there was limited
structural information available to provide support with
molecular modeling tools for identifying GPR84 antagonists.
The closest homologs of GPR84 with resolved structures had
sequence identities below 30%, thereby preventing homology
models being developed with sufficient accuracy to enable
structure-based design. Furthermore, ligand-based approaches
were limited due to the absence of reference antagonists. These
issues led us to rely on a high-throughput screen (HTS)
approach to identify GPR84 antagonists.
A functional assay based on measurement of cyclic
adenosine 3′,5′-monophosphate (cAMP) was selected to
detect antagonists from a collection of approximately
200 000 diverse compounds. The comparison of assay
robustness between the cAMP assay and the orthogonal
assay ([35S]guanosine 5′-O-[γ-thio]triphosphate (GTPγS)
binding) led us to use the GTPγS for hit confirmation and
concentration−response determination. The GTPγS assay
measures the level of G protein activation following agonist
occupancy of a GPCR by determining the binding of the
nonhydrolyzable analogue [35S]GTPγS to Gα subunits using
membranes derived from a HEK293 cell line stably over-
expressing human GPR84.
Through HTS, the commercially available compound 2-
(benzylamino)-9,10-dimethoxy-6,7-dihydro-4H-pyrimido[6,1-
a]isoquinolin-4-one (1) (Table 1) was identified as an
appropriate starting point with submicromolar potency (IC50
= 735 nM) combined with favorable druglikeness properties,20
such as moderate lipophilicity (XlogP3 = 2.4), polar surface
area (PSA = 63.2), and molecular weight (MW = 363.4).
Compound 1 showed moderate in vitro metabolic clearance
in both mouse and human microsomes and hepatocytes (Table
1). In vivo intravenous (iv) dosing at 1 mg/kg in Sprague
Dawley rats confirmed a moderate plasma clearance and
revealed a moderate volume of distribution and short terminal
half-life (Table 1).
The favorable physicochemical parameters of 1 translated
into high apparent permeability in Caco-2 cells with a low
efflux ratio (Table 1). When administered orally to Sprague
Dawley rats at 5 mg/kg in polyethylene glycol (PEG) 200/
H2O (60/40; v/v), high plasma exposure (Cmax = 1269 ng/mL
and AUC0−inf = 2588 ng·h/mL) was obtained for 1 with a 50%
oral bioavailability (Table 1). The hit series did not show
marked inhibition of either cytochrome P450 (CYP) or human
ether-a-̀go-go-related gene (hERG).
At the start of our investigations, the presence of two
methoxy groups in the 9 and 10 positions of the isoquinoline
moiety raised some concerns, as such groups might play the
role of the catechol ether structural motif common to most of
the phosphodiesterase 4 (PDE4A) inhibitors21,22 and
introduce a PDE4A inhibitory component to the hit series
already reported for 9 and 10 substituted dialkoxy analogues of
pyrimido[6,1-a]isoquinolin-4-ones.23
PDE4 inhibitors possess a broad range of anti-inflammatory
effects but have pronounced nausea and emesis side effects. As
the aim of this project was to generate selective antagonists
allowing us to unequivocally assess the therapeutic potential of
GPR84, we wanted to show less than 50% inhibition over
PDE4A at 10 μM. PDE4A inhibitory activity of 1 was
confirmed (IC50 = 553 nM; Table 1). This led us to implement
a PDE4A biochemical assay to assess the inhibitory activity of
Figure 1. Chemical structures of known GPR84 agonists MCFA C10,
embelin, 2-HTP, and DIM derivatives and the GPR84 antagonists
PBI-4050 and 6-OAU. Abbreviations: 2-HTP, 2-(hexylthiol)-
pyrimidine-4,6 diol; 6-OAU, 6-n-octylaminouracil; DIM, 3,3′-
diindolylmethane; MCFA, medium-chain free fatty acids.
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the compounds and gain SAR (structure−activity relationship)
understanding to remove this residual PDE4A activity.
Initial SAR investigations focused on modifications of the
benzyl amine moiety. Potency was abolished by either
replacement of the nitrogen atom by a carbon atom (2) or
introduction of a carbon−carbon double bond in place of the
amino-methyl linker (3) (Table 2). A more favorable
replacement was identified with the introduction of an oxygen
atom, leading to an encouraging 5-fold increase in potency (4),
compared with 1 (Table 2). We decided to consolidate the
investigations with the oxygen atom in place.
Improved potency (IC50 = 21 nM, Table 2) was observed
with the introduction of an aliphatic chain that is common to
the MCFA endogenous ligands (5), although solubility was
drastically reduced by the lipophilic side chain (aqueous
solubility [ASOL] pH 7.4 = 3 μg/mL).
Various lipophilic spacers were introduced (6 and 7) and
showed decreased potency compared with 4 (Table 2). With
this ether linkage in place, introduction of a fluorine in the
ortho position (8) had limited impact on potency, compared
with 4. Further assessment of PDE4A inhibitory activity
Table 1. Properties of Hit Compound 1a
hGPR84 GTPγS IC50 (nM) 735
PDE4A IC50 (nM) 553
aqueous solubility 2% DMSO (μg/mL)
pH 3/pH 7.4 >73/24
liver microsomal stability
CLint MIC scaled (L h
−1 kg−1) mouse: 10.4 (n = 2)
human: 1.9 (n = 2)
hepatocyte stability
CLint HEP scaled (L h
−1 kg−1) mouse: 10.6 (n = 2)
human: 1 (n = 2)
intestinal permeability Caco-2 cells
Papp A2B (10
−6 cm/s)/ER 15/2.0 (n = 2)
hCYP inhibition
% inhibition at 10 μM <33 with CYP1A2, CYP2C19,
CYP2C9, CYP2D6, CYP3A4
(midazolam and testosterone)




rat PK 1 mg/kg iv
T1/2 (h) 0.89
CL (L h−1 kg−1); CL (% LBF) 1.06; 21.6
Vss (L/kg) 1.27
aAbbreviations: AUC0−inf, area under curve (from time 0 to infinity);
CLint, intrinsic clearance; Cmax, maximum plasma concentration;
DMSO, dimethyl sulfoxide; ER, efflux ratio; hCYP, human
cytochrome P450; F, oral bioavailability; GTPγS, guanosine 5′-O-
[γ-thio]triphosphate; HEP, hepatocyte; hGPR84, human G-protein-
coupled receptor 84; IC50, half maximal inhibitory concentration; iv,
intravenous; LBF, liver blood flow; MIC, microsomal; MW, molecular
weight; Papp A2B, apparent permeability from apical to basal
chambers; PDE4A, phosphodiesterase 4; PK, pharmacokinetics; po,
per os; PSA, polar surface area; T1/2, half-life; Vss, apparent volume of
distribution at steady state.
Table 2. hGPR84 GTPγS, PDE4A, Human Neutrophil
Migration, and Solubility Profiles of 1 Derivativesa
aAbbreviations: ASOL, aqueous solubility; Cap, capric acid; Compd,
compound; hGTPγS, human guanosine 5′-O-[γ-thio]triphosphate;
Hum neutro, human neutrophil migration assay; IC50, half maximal
inhibitory concentration; IP1, inositol monophosphate; PDE4A,
phosphodiesterase 4.
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showed no selectivity improvement. Moreover, 8 showed
decreased metabolic stability in mouse microsomes (Table 3),
compared with 1.
We probed the scope of polarity introduction which, if
tolerated, could be beneficial for further improvement of
metabolic stability. The addition of an ethylene glycol spacer
(9) restored good potency (IC50 = 63 nM) and gave a 150-fold
increase compared with the match paired analogue (7) (Table
2). This disparity indicated a strong contribution from the
oxygen atom introduced, possibly resulting from an H-bond
interaction. Compound 9 showed a reduced inhibitory activity
on PDE4A (Table 2), leading to a 30-fold ratio selectivity.
Table 3. hGTPγS, PDE4A, and Mouse Liver Microsomal Stability of Substructural Derivativesa
aAbbreviations: Compd, compound; CLint, intrinsic clearance; hGTPγS, human guanosine 5′-O-[γ-thio]triphosphate; IC50, half maximal inhibitory
concentration; LMS, liver microsomal stability; Me, methyl group; PDE4A, phosphodiesterase 4.
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Internal investigations identified that GPR84 agonists such as
embelin, DIM, and sodium decanoate were able to induce
human neutrophil migration. GPR84 antagonists were able to
specifically block neutrophil chemotaxis induced by GPR84
agonists (Supplemental Figure 4). The embelin-induced
neutrophil chemotaxis assay was used as an inflammatory
disease relevant cell assay to determine the inhibitory activity
of our GPR84 antagonists. Assessment of 9 showed a good
translation of the antagonist effect on a target based GTPγS
assay toward the human neutrophil migration assay (IC50 =
128 nM; Table 2). Comparing the matched pairs 10 and 8
showed that the introduction of one nitrogen atom had only a
moderate impact on potency; however, a positive impact was
observed on metabolic stability (Table 3) and its selectivity
toward PDE4A (IC50 = 1088; Table 2).
Replacement of the phenyl ring with a more polar
tetrahydrofuran was tolerated for the 2-substituted heterocycle
(11) and found inactive for the 3-substituted analogue (12)
Table 4. hGTPγS, PDE4A, Liver Microsomal Stability, Hepatocyte Stability, PPB, and XlogP3 Profiles for Substructural
Derivativesa
aAbbreviations: CLint, intrinsic clearance; H, human; HEP, hepatocyte; hGTPγS, human guanosine 5′-O-[γ-thio]triphosphate; IC50, half maximal
inhibitory concentration; M, mouse; MIC, microsomal; PPB, plasma protein binding; PDE4A, phosphodiesterase 4; R, rat.
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(Table 2). This result is associated with the favorable impact
observed on potency with the oxygen introduction (9) and
may be indicative of a specific interaction of GPR84 with an
oxygen atom in this position. In addition to increased potency,
the position of oxygen in 11 improved selectivity against
PDE4A (IC50 = 2165 nM; Table 2) and solubility (9, ASOL
pH 7.4 = 26 μg/mL and 11, ASOL pH 7.4 = 72 μg/mL). The
potency of 9, in the human neutrophil assay (IC50 = 128 nM;
Table 2), prompted investigation into the tolerance of further
polarity. Replacement of the phenyl ring of 9 with a 2-pyridyl
ring increased both the potency toward the target and the
selectivity ratio over PDE4A (13, GTPγS IC50 = 8 nM and
selectivity ratio = 73).
Sequence differences between human and mouse GPR84
(mouse GPR84 shares 85% with its human ortholog at the
amino acid level) prompted us to assess activity of the hit
series on mouse GPR84 receptor assays. At this stage of
investigation, no cell line stably overexpressing the mouse
receptor for the GTPγS assay was available. An assay
measuring inositol monophosphate (IP1) using transiently
transfected HEK293 cells with either the human or mouse
recombinant GPR84 and a variant of a chimeric Gq protein
was developed to allow direct comparison on mouse and
human receptor under similar assay conditions. We confirmed
the high inhibitory activity of 13 in the IP1-based hGPR84
assay (hGPR84 IP1 IC50 = 11 nM) and observed an
approximate 60-fold reduction in the IP1-based mouse
GPR84 assay (mGPR84 IP1 IC50 = 636 nM).
Initial investigations demonstrated that a high potency in the
nanomolar range could be reached in the human GTPγS assay,
which translated into potent inhibition of human neutrophil
migration. Further optimization comprised the consolidation
of the attractive profile of the series, with the aim to improve
the selectivity ratio by producing a compound that was inactive
in the PDE4A assay or had at least a 100-fold selectivity.
The presence of the catechol ether moiety in known potent
inhibitors of PDE4A suggested a key role for this functional
group in the enzyme pharmacophore, prompting further
investigation of the impact of modifications in this region.
The presence of the two methoxy substituents was found to be
crucial to PDE4A activity but not mandatory for maintaining
GPR84 inhibitory activity, as illustrated with the unsubstituted
analogue 14 (Table 3). Removal of either methoxy group
markedly decreased PDE4A activity for the corresponding
analogues (15 and 16; Table 3). Of particular interest were the
9-methoxy substituted analogues, which showed a less than 10-
fold loss of GPR84 activity in three matched pairs (17 and 10;
18 and 11; 15 and 8; Table 3). The favorable selectivity trend
was found to be well conserved when applied to the 2-
fluoropyridine analogue (17 and 10; Table 3). Despite
decreased metabolic stability in mouse liver microsomes
observed for the 9-substituted analogue 17 compared with
the dimethoxy substituted analogue 10 (Table 3), the gain in
selectivity and the attractiveness of the undocumented 9-
methoxy derivatives led us to continue in this direction.
Introduction of the phenoxyethyl group (19) led to a 20-
fold increase in potency compared with the moderately potent
starting point 18 (Table 4), a marked improvement from the
previous 6-fold increase in potency for the dimethoxy
substituted matched pair analogues 11 and 9. Additionally,
Table 5. hGTPγS, XlogP3, Metabolic Stability, and Permeability Profiles of 25, 26, and 27a
aAbbreviations: CLint, intrinsic clearance; Compd, compound; ER, efflux ratio; hGTPγS, human guanosine 5′-O-[γ-thio]triphosphate; IC50, half
maximal inhibitory concentration; MIC, minimum inhibitory concentration; Papp A2B, apparent permeability from apical to basal chambers.
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19 achieved good selectivity with an inhibitory activity above
10 μM in the PDE4A assay (Table 4). Within the chemical
series, the preliminary results observed from liver microsomal
stability data and the lipophilicity of the compounds seemed to
point toward a favorable XlogP3 threshold below 3.
Subsequent SAR optimization aimed to keep lipophilicity
with XlogP3 below 3, retain the key β-oxygen, and determine
the most suitable moieties for demonstrating a good metabolic
profile while maintaining acceptable potency and selectivity.
Replacement of the 2-tetrahydrofuryl with the homologous
tetrahydro-2H-pyranyl moiety improved potency (20; Table 4)
with a moderate increase in lipophilicity. However, a significant
reduction in lipophilicity was achieved with the introduction of
the 1,4-dioxane (21) with similar potency compared with 20
and improved metabolic stability in mouse and human liver
microsomes and hepatocytes. The attractive absorption,
distribution, metabolism, and excretion (ADME) profile
obtained by introduction of the dioxane moiety prompted
attempts to mitigate the associated reduced potency by adding
moderate lipophilicity with fused heterocycles on the dioxane.
This was achieved through fusion of a phenyl ring to produce
22 with increased potency (IC50 = 50 nM; Table 4) but with
severely reduced stability in mouse, rat, and human liver
microsomes.
To reduce the lipophilicity, a 2-pyridyl ring was fused to the
dioxane to give 23. However, the introduction of the nitrogen
in the ortho position of the key β-oxygen resulted in reduced
potency compared with 22. Introducing the nitrogen to the
ortho position of the other oxygen in the dioxane ring had a
positive impact on potency (24) but was accompanied by a
high intrinsic liver microsomal clearance in mice (Table 4).
Assessment of the metabolic stability of compounds 18−24 in
hepatocytes showed a good correlation of intrinsic clearance
between liver microsomes and both mouse and human
hepatocytes, indicating a major contribution in phase I
metabolism (Table 4).
With the high potency of 24, further optimization
investigations focused on modifications of the 9 position
with opportunistic introduction in one step of diverse and
exotic commercially available moieties (Table 5). Assessment
of the tolerability of this region to substantial modulation was
investigated through the introduction of a negatively charged
chain and a very bulky moiety. Interestingly, substitution of the
methyl group with an acetic acid group from the potent
compound 22 led only to a moderate 5-fold decrease in
potency (25; Table 5). Replacement of the methoxy group
with 2-cyanophenyl (26) was neutral (IC50 = 212 nM; Table
5) when compared with 21. The compound was unstable in
dog, monkey, and human liver microsomes, but moderate
clearance was observed in rodents. Furthermore, 26 demon-
strated good permeability in Caco-2 cells with low efflux and
high systemic exposure in rat at 5 mg/kg (AUC0−Z of 2645 ng·
h/mL [6.37 μM·h] following oral dosing in PEG200/water
[60/40; v/v]) providing an interesting opportunity to evaluate
the capability of the lead series to modulate inflammatory
bowel disease (IBD).
To assess in vivo efficacy, 26 was studied in a mouse chronic
dextran sodium sulfate (DSS)-induced colitis model, a well-
validated model for IBD.24,25 The DSS treatment significantly
increased the disease activity index (DAI) score (sum of scores
for weight loss, stool consistency, and fecal blood) reflecting
active colitis. As expected, once-daily treatment with the
positive control cyclosporine (administered at 25 mg/kg, once
daily [qd]) diminished the DAI score in diseased mice. Once-
daily treatment with 26 at 10 mg/kg qd reduced the DAI score
at 8−11 days (p < 0.05 at day 9 versus diseased mice) (Figure
2). Encouraged by these in vivo data, subsequent optimization
of the lead series was aimed at improving in vivo potency and
metabolic stability in dog and human.
A 33-fold gain in potency was achieved by the addition of a
bulky phenylpro-2-yn-1-ol moiety to the highly potent
compound 24 to produce 27 with a subnanomolar potency
on GPR84 (IC50 = 0.6 nM; Table 5). This result confirmed the
option of replacing the oxygen linker at the 9 position with a
carbon atom, as with 26. These additions, of both the
negatively charged chain and bulky moiety, indicated a broad
Figure 2. Disease activity index score in a mouse DSS-induced chronic colitis model. Diseased mice were administered with 4% DSS in drinking
water for 4 days, followed by 3 days of regular drinking water and a new cycle of DSS. In addition they were orally administered 26 at 10 mg/kg
once daily (qd), cyclosporine at 25 mg/kg qd (positive control), or vehicle for 11 consecutive days. Control mice were administered water alone as
a negative control. Data are the mean ± SEM. No scores were measured on days 5 and 6.
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SAR tolerance in this region of the molecule. Further
modification of this region was pursued with the aim of
maintaining overall lipophilicity below the defined threshold
for the series while benefiting from a gain in potency.
The high potency of 27 was associated with increased
lipophilicity (Table 5), so further modifications aimed to
achieve a good balance of these properties. The moderately
potent 21 (Table 4) was selected as a starting compound as it
afforded a 2 log margin for lipophilicity and required only an
approximate 10-fold gain in potency to produce an attractive
target molecule. Removal of the 9-methoxy substituent (28;
Table 6) had a minor impact on the lipophilicity and the
Table 6. hGTPγS, XlogP3, PDE4A, IP1, Liver Microsomal Stability, and Human Neutrophil Migration Profiles of
Substructural Derivativesa
aAbbreviations: CLint, intrinsic clearance; Compd, compound; D, dog; H, human; hGTPγS, human guanosine 5′-O-[γ-thio]triphosphate; Hum
neutro, human neutrophil migration; IC50, half maximal inhibitory concentration; IP1, inositol monophosphate; LMS, liver microsomal stability; M,
mouse; MIC, microsomal; PDE4A, phosphodiesterase; R, rat.
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inhibitory activity (Table 6). Introduction of groups with
growing size to maintain lipophilicity in the targeted range
improved the potency (29, 30, and 31; Table 6). Introduction
of a 2 ethylpyridyl moiety maintained a moderate lipophilicity
and gave a remarkable potency (32) in human GTPγS and IP1
assays and reduced orthology shift in the mouse IP1 assay.
However, while the compound showed low clearance in
human microsomes (intrinsic clearance (CLint) scaled of 1.5 L
h−1 kg−1), it was highly cleared in mouse liver microsomes
(CLint scaled of 31 L h
−1 kg−1) precluding further in vivo
evaluation of the compound.
We decided to further exploit the initial path identified with
compound 27 (Table 5). Starting from a decreased level of
lipophilicity, due to the removal of the fused pyridyl moiety,
the phenyl ring linked to the secondary alcohol was replaced
with an isobutyl group limiting the lipophilicity at XlogP3 =
2.3. Compound 33 showed good potency (IC50 = 25 nM;
Table 6); however, in spite of a moderate lipophilicity, the
compound was found to be insufficiently stable in rat liver
microsomes (CLint scaled of 15.3 L h
−1 kg−1). Compound 34
was designed to remove the propargylic alcohol as a putative
metabolite site and introduce a basic benzyl amine moiety.
These modifications retained potency (IC50 = 22 nM; Table
6), but 34 showed elevated liver microsomal clearances in both
mouse and human (in mouse, CLint scaled of 26 L h
−1 kg−1 and
in human, CLint scaled of 5.3 L h
−1 kg−1).
The addition of a simple cyclopropyl ring into the alkyne
moiety maintained both acceptable lipophilicity and potency
(IC50 = 55 nM; Table 6), and the resulting compound 35 was
devoid of PDE4A activity. The high potency of the compound
was confirmed in a human IP1 assay (IC50 = 2 nM) and was
found to be 10-fold less potent in the same assay in mice (IC50
= 21 nM). In accordance with previous data, the high potency
of 35 in GPR84 functional assays corresponded to high
potency in human neutrophil migration assays (IC50 = 17;
Table 6). A rat neutrophil migration assay was successfully
developed and confirmed the high inhibitory activity of the
compound (IC50 = 119 nM) and the shift in activity from
human to rodent. Additionally, 35 showed acceptable
metabolic stability in human, rat, and mouse liver microsomes
(CLint scaled of 2.2, 1.4 and 9.7, respectively).
The attractive profile of 35, with good potency in rat and
human in vitro assays and improved metabolic stability in
human liver microsomes, led to further in vivo studies. High
plasma exposure was observed following oral administration at
5 mg/kg in rats with an AUC0−inf of 10246 ng·h/mL and a Cmax
of 2423 ng/mL at 1.7 h. In a mouse DSS-induced chronic IBD
model, once-daily treatment with 35 at 1, 3, or 10 mg/kg dose-
dependently reduced the DAI score; 35 at 10 mg/kg was found
to have similar efficacy as cyclosporine at 25 mg/kg, the
positive control (Figure 3).
The attractive profile of the compound instigated efforts to
isolate and characterize the two enantiomers of 35 (Table 7).
When profiled in terms of ADME and biological assays, the
two enantiomers (S) 36 and (R) 37 showed moderate
differences favoring the (S) enantiomer 36 (Table 7).
Compound 36 was approximately 5-fold more potent in
human neutrophil migration assays (Table 7) but only slightly
more potent in human GTPγS and rat and dog neutrophil
migration assays (Table 7). Both enantiomers appeared stable
in hepatocytes when incubated at 1 μM, with a low predicted
hepatic clearance for rat, mouse, dog, and human (Table 7).
The two enantiomers did not show marked differences in
binding to plasma protein when assessed in four different
species in an in vitro equilibrium dialysis PPB assay (tested at 5
μM) (Table 7). The assessment of the CYP inhibitory
potential of the two enantiomers was markedly more favorable
for 36. The IC50 was determined using human liver
microsomes with probe substrates for CYP1A2, 2C9, 2C19,
2D6, and 3A4 (Table 7). The IC50 value for 36 for each of the
CYP isoenzymes was >33 μM (Table 7), whereas the (R)
enantiomer showed micromolar inhibition of the CYP2C9
isoform (IC50 = 1.85 μM; Table 7) and moderate inhibition of
CYP2C19 (IC50 = 18 μM; Table 7). In addition, there was no
evidence for time-dependent inhibition of CYP3A4 by 36
(human liver microsomes, midazolam, and testosterone used as
Figure 3. Disease activity index score in a mouse DSS-induced chronic colitis model. Diseased mice were administered with 4% DSS in drinking
water for 4 days, followed by 3 days of regular drinking water and a new cycle of DSS. In addition they were orally administered 35 at 1*, 3† or 10‡
mg/kg qd, cyclosporine at 25 mg/kg qd (positive control), or vehicle, for 11 consecutive days. Control mice were administered water alone as a
negative control. Data are the mean ± SEM. No scores were measured on days 5 and 6.
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probe substrates to assess remaining enzyme activity) and the
IC50 was >50 μM, both with and without preincubation.
The pharmacokinetic profile (PK) of 36 was assessed in
three species (mouse, rat, and dog) after an iv administration
at 1 mg/kg (in mouse) or 0.5 mg/kg (in rat and dog) and an
oral administration in fasted animals at 5 mg/kg (in mouse) or
2.5 mg/kg (in rat and dog). PEG200/NaCl 0.9% (60/40; v/v)
was used as formulation for the iv route and PEG200/water
(60/40; v/v) for the po route. A high oral exposure was
obtained in all three species (Table 8), giving a bioavailability
of 100%. A high total clearance was observed in dogs but did
not preclude its progression owing to acceptable clearances in
other species. The use of the recently introduced unbound
clearance parameter shows that this is due to the lower PPB in
dog (93.5% of binding) compared with mouse, rat, and human,
leading to a lower unbound clearance (CLunb = 18.5). The
volume of distribution was low in mice and high in dogs.
In competition studies, 36 was found to block agonist effects
of both modulators considered as orthosteric ligands, such as
C10 and embelin, and allosteric ligands, such as PSB-16671
(Figures 1 and 4A). In parallel to the progression of 36,
additional potent compounds with modified substitutions in
position 9 and different side chains in the northern region of
the compound were identified. Compound 38, with a
phenethyl chain in position 9 and a 2-ethoxypyrazine moiety
in the northern region (Figure 4B), reached a high potency
level in the hGTPγS assay (IC50 = 5 nM). In addition to being
one of the most potent analogues in the GTPγS assay, the
straightforward synthetic introduction of a tritium atom into
the molecule from the corresponding 3-chlorophenetyl
derivative guided the selection of 38 as a target for generating
a radiolabeled ligand ([3H]38 was prepared by Quotient
Bioresearch). Compound 36 competed well with its analogue
[3H]38 with a pKi of 7.52. Increasing concentrations of C10
were unable to displace the [3H]38 ligand, suggesting an
allosteric binding site for the GPR84 antagonists (Figure 4C).
In the same competition experiment, PSB-16671, an allosteric
agonist from the DIM series, showed only moderate
displacement at a very high dose (Figure 4C). In a Schild
experiment, further characterization of the interaction between
the two ligands showed 36 to act dose-dependently as a
noncompetitive and reversible blocker of PSB-16671, with a
decreased maximum effect rather than markedly increasing the
half maximal effective concentration (EC50) (Figure 4D).
These results, combined with previous studies showing that
[3H]38 binding was not affected by mutation of key residue
Arg172,26 indicate that 36 acts as a negative allosteric
modulator of the known GPR84 agonists.
In a mouse DSS-induced chronic IBD model, once-daily
treatment with 36 at 3 or 10 mg/kg reduced the DAI score
(Figure 5A). In the colon, compound 36 also reduced
neutrophil infiltration induced by DSS, a pharmacodynamics
marker in relation to in vitro neutrophil chemotaxis activity
(Figure 5B). The pharmacodynamics marker was reversed by
36 at 3 mg/k and 10 mg/kg, with a similar dose effect to DAI.
This provides a mechanistic insight, clearly indicating the
capacity of 36 to reduce neutrophil migration toward the
inflamed colonic tissue. This activity was associated with a Cmax
of 1837 ng/mL and an exposure level (AUC0−24h) of 5556 ng·
h/mL (Table 9).
Compound 36 was tested in three independent mouse DSS-
induced chronic IBD studies at 1, 3, or 10 mg/kg to confirm
the efficacy and to define the minimal efficacious dose (MED).
The dose of 1 mg/kg dose was inactive; however the dose of 3
mg/kg was constantly found active in all three studies and thus
was considered as the MED.
Compound 36 was further profiled in a diverse set of
selectivity assays. Compound 36 was fully selective over close
homologs GPR43 (FFA2R) and GPR41 (FFA3R) (no
inhibition up to 10 μM in [Ca2+]i flux assay) and >100-fold
selective over 123 other GPCRs on a Millipore GPCR Profiler
panel. Compound 36 was remarkably selective over a kinase
Table 7. Profiles of the Two Enantiomers of 35a
36 (S) 37 (R)
hGPR84 (GTPγS IC50, nM) 54 102
human neutrophil assay (IC50, nM) 11 51
rat neutrophil assay (IC50, nM) 111 153
dog neutrophil assay (IC50, nM) 75 111
aqueous solubility 2% DMSO (μg/mL)
pH 3/pH 7.4 113/113 113/113
thermodynamic solubility (μg/mL)
pH 3/pH 7.4 12.6/7.75 17.6/9.49
liver microsomal stability 1 μM
CLint MIC scaled (L h




hepatocyte stability 1 μM
















intestinal permeability Caco-2 cells
Papp A2B (×10
−6 cm/s)/ER 41.9/1.05 31.2/1.07




3A4 mid >50 >50
3A4 test >50 >50




aAbbreviations: CLint, intrinsic clearance; CYP, cytochrome P450;
DMSO, dimethyl sulfoxide; ER, efflux ratio; GTPγS, guanosine 5′-O-
[γ-thio]triphosphate; HEP, hepatocyte; HLM, human liver micro-
some; IC50, half maximal inhibitory concentration; IP1, inositol
monophosphate; MIC, microsomal; Papp A2B, apparent permeability
from apical to basal chambers; PPB, plasma protein binding.
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panel, displaying only weak inhibitory activity against maternal
embryonic leucine zipper kinase (MELK; 57% inhibition at a
concentration of 10 μM) out of a selection of 152 kinases
(Reaction Biology, Malvern, PA, USA); this inhibitory activity
was not considered to be clinically relevant. Similar high
selectivity was also observed against a diverse panel of 67
enzymes focusing mostly on ion channels and transporters.
Compound 36 was considered to present a low cardiovascular
risk due to the minimal impact observed on the amplitude of
the IKr current in the in vitro hERG manual patch clamp assay
and the lack of effect on hemodynamic and electrocardio-
graphic parameters in telemetered monkeys. Compound 36
was assessed in the full Ames test, up to concentrations of 5000
μg/plate, in the presence and absence of S9 fraction, leading to
the conclusion that 36 is not mutagenic in the Salmonella
typhimurium reverse mutation assay and in the Escherichia coli
reverse mutation assay. Compound 36 did not have any
genotoxic effect in vitro in the mouse lymphoma assay or in
vivo in the bone marrow micronucleus test in rats. Compound
36 did not show any teratogenic or embryotoxic effects in rats,
up to the highest tolerated maternal dose of 50 mg kg−1 day−1.
In addition, no phototoxic effects with 36 have been observed
in vivo in rats and mice.
■ CHEMISTRY
GLPG1205 Synthesis. GLPG1205 (36) was synthesized in
nine linear steps that all proceeded with yields higher than 70%
and involved readily available starting material (Scheme 1).
Starting from 3-methoxyphenethylamine, refluxing urea in
acetic acid overnight led to the urea analogue. Demethylation
was carried out upon overnight reflux with hydrogen bromide
to lead to the corresponding phenol derivative which was
further protected by introduction of an allyl group.
Condensation with diethyl malonate afforded the hexahy-
dropyrimidine-2,4,6-trione which underwent regioselective
cyclization reaction with treatment with POCl3. Subsequent
O-alkylation with commercially available or easily prepared
(R)-(1,4-dioxan-2-yl)methanol27 followed by deprotection of
the allyl group led to the phenol intermediate. The phenol
intermediate was converted into the corresponding triflate for
further use in Sonogashira coupling reaction with ethynylcy-
clopropane, providing GLPG1205. The purity of all com-
pounds was determined by liquid chromatography−mass
spectrometry (LCMS) and 1H NMR. Minor adaptations of
this synthetic route afforded 9,10-dimethoxy derivatives
starting from 3,4-dimethoxyphenethylamine.
■ CONCLUSION
The progression of the commercially available hit compound 1
to the clinical candidate 36 was achieved by structure
optimization to improve potency (GTPγS assay), metabolic
stability, lipophilicity, and selectivity against PDE4A. In a
mouse DSS-induced chronic IBD model, treatment with 36
reduced both the DAI score and neutrophil infiltration at oral
doses of 3 and 10 mg/kg qd, with an efficacy similar to the
positive control compound sulfasalazine. A phase I first-in-
human study28 and a phase IIa study in IBD (ulcerative colitis;
NCT02337608)29 confirmed favorable PK, safety, and
tolerability profiles for 36, but the compound failed to meet
the primary efficacy end point in the latter, and as GLPG1205
is the first in class GPR84 antagonist tested in clinical study,
additional translational studies would contribute to the further
understanding of results.29 The biology of GPR84 has been
further investigated and a potential role in fibrosis described in
different organs including the kidney16 and liver.30 Moreover,
GLPG1205 (36) has demonstrated reduced lung fibrosis in
two mouse models in a therapeutic setting.31 GLPG1205 (36)
is currently being evaluated in a phase II study in patients with
idiopathic pulmonary fibrosis. Additional safety, pharmaco-
logical, PK, and clinical data will be reported in due course.
■ EXPERIMENTAL SECTION
Chemistry. Methods. All reagents were of commercial grade and
were used as received without further purification unless otherwise
stated. Commercially available anhydrous solvents were used for
reactions conducted under inert atmosphere. Reagent grade solvents
were used in all other cases unless otherwise specified. Column
chromatography was performed on silica gel 60 (35−70 μm). Thin
layer chromatography was carried out using precoated silica gel F-254
plates (thickness 0.25 mm). Microwave heating was performed with a
Biotage Initiator apparatus (Biotage, Uppsala, Sweden). Celpure P65
(Merck KgaA, Darmstadt, Germany) is a filtration aid and commercial
product (CAS number 61790-53-2). 1H NMR spectra were recorded
on a Bruker DPX 400 NMR spectrometer (400 MHz) (Bruker,
Billerica, MA, USA) or a Bruker Avance 300 NMR spectrometer (300
MHz) (Bruker, Billerica, MA, USA). Chemical shifts (δ) for 1H NMR
spectra are reported in parts per million (ppm) relative to
tetramethylsilane (δ 0.00) or the appropriate residual solvent peak,
i.e., CHCl3 (δ 7.27), as internal reference. Multiplicities are given as
singlet (s), doublet (d), triplet (t), quartet (q), quintuplet (quin),
multiplet (m), and broad (br). Waters Acquity UPLC (Waters,
Elstree, U.K.) with Waters Acquity PDA detector (Waters, Elstree,
U.K.) and SQD mass spectrometer (Waters, Elstree, U.K.) were used
to generate UV and MS chromatograms as well as MS spectra.
Columns used were the following: UPLC BEH C18 1.7 μm, 2.1 mm














C0 or Cmax (ng/mL) 1227 4593 395 1164 NC 558
Tmax (h) 0.5 1.5 0.5
AUC(0−24h) (ng·h/mL) 1054 15349 710 4469 410 2232
CL (L h−1 kg−1)/(% LBF) 0.9/11 0.7/14 1.2/48
CLunb (L h
−1 kg−1) 40.9 30.4 18.5
Vss (L/kg) 0.6 1.2 2.0
t1/2 (h) 0.6 1.9 1.0 1.3 1.4 2.0
F (%) >100 >100 >100
aAbbreviations: AUC, area under curve; CL, clearance; CLunb, clearance unbound calculated using PPB data (Table 7); Cmax, maximum plasma
concentration; C0, concentration extrapolated at T0 after a bolus iv dose; F, bioavailability; LBF, liver blood flow; t1/2, half-life; Tmax, time at Cmax;
Vss, volume of distribution.
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× 5 mm, VanGuard Precolumn (Waters, Elstree, U.K.) with Acquity
UPLC BEH C18 1.7 μm, 2.1 mm × 30 mm column or Acquity UPLC
BEH C18 1.7 μm, 2.1 mm × 50 mm column. LC−MS analyses were
conducted using the following two methods. Method 1: solvent A,
H2O−0.05% NH4OH; solvent B, MeCN−0.05% NH4OH; flow rate,
0.8 mL/min; start 5% B, final 95% B in 1.55 min, linear gradient.
Figure 4. (A) Effect of increasing concentrations of 36 on effects of orthosteric and allosteric GPR84 agonists (GTPyS assay with agonists used at
EC80). (B) Structure of tritiated ligand 38. (C) Ability of various concentrations of C10, PSB-16671, and 36 to compete for binding with [
3H]38 to
GPR84 (competition binding + 0.2 nM [3H]38). (D) Schild analysis showing inhibition of PSB-16671 activity with 36 at concentrations of 10 nM,
30 nM, 100 nM, and 300 nM.
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Method 2: solvent A, H2O−0.1% HCO2H; solvent B, MeCN−0.1%
HCO2H; flow rate, 0.8 mL/min; start 5% B, final 95% B in 1.55 min,
linear gradient. All final compounds reported were analyzed using one
of these analytical methods, and purity is greater than 95% or
otherwise indicated in the Supporting Information. Autopurification
system from Waters was used for LC−MS purification. LC−MS
columns used: Waters XBridge Prep OBD C18 5 μm, 30 mm × 100
mm (preparative column) and Waters XBridge BEH C18 5 μm, 4.6
mm × 100 mm (analytical column) (Waters, Elstree, U.K.). All the
methods used MeCN/H2O gradients. MeCN and H2O contained
either 0.1% formic acid or 0.1% diethylamine.
2-(3-Methoxyphenyl)ethylurea. A solution of 3-methoxyphe-
nethylamine (100 g, 661.3 mmol), urea (157.3 g, 2619.0 mmol),
glacial AcOH (36 mL), and concentrated HCl (12 mL) in H2O (800
mL) was heated under reflux for 5 days. The reaction mixture was
cooled to room temperature (RT), and the precipitate obtained was
filtered off, washed with water, and dried under vacuum to give 2-(3-
methoxyphenyl)ethylurea as a white solid (92 g, 72% yield). 1H NMR
(400 MHz, methanol-d4) δ 7.18 (t, J = 8.1 Hz, 1H), 6.83−6.71 (m,
3H), 3.77 (s, 3H), 3.37−3.31 (m, 2H), 2.74 (t, J = 7.2 Hz, 2H).
2-(3-Hydroxyphenyl)ethylurea. A solution of 2-(3-
methoxyphenyl)ethylurea (92 g, 473.6 mmol) in concentrated HBr
(600 mL) was heated under reflux overnight. The reaction was cooled
to RT and basified by addition of NaHCO3 and extracted with
EtOAc. The organic layer was dried over MgSO4, filtered, and
concentrated under reduced pressure to give crude 2-(3-
hydroxyphenyl)ethylurea as a light brown solid (67 g) which was
used in the next step without further purification. 1H NMR (400
MHz, DMSO-d6) δ 9.25 (s, 1H), 7.07 (td, J = 7.2, 1.8 Hz, 1H), 6.65−
Figure 5. Diseased mice (DSS-induced chronic colitis model) were administered with 4% DSS in drinking water for 4 days, followed by 3 days of
regular drinking water and a new cycle of DSS. In addition they were orally administered 36 at 3* and 10† mg/kg qd, sulfasalazine 20 mg/kg qd
(positive control) or vehicle, for 11 consecutive days. Control mice were administered water alone as a negative control. (A) Disease activity index
score. Data are the mean ± SEM. No scores were measured on days 5 and 6. (B) Neutrophil density (number of cells per square millimeter of
colon area, as determined by immunohistochemistry assay with anti-Ly6G/Ly6C antibodies).
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6.55 (m, 3H), 5.89 (t, J = 5.8 Hz, 1H), 3.16 (dt, J = 7.7, 6.3 Hz, 2H),
2.57 (t, J = 7.3 Hz, 2H). LCMS: m/z 181 [M + H]+.
2-(3-Allyloxyphenyl)ethylurea. To a solution of crude 2-(3-
hydroxyphenyl)ethylurea (67 g, 371.0 mmol) and K2CO3 (154 g,
1115.0 mmol) in DMF (400 mL) was added allyl bromide (75 mL,
743.6 mmol), and the reaction was stirred for 2.5 days. DMF was
concentrated under reduced pressure and then the residue was
dissolved in EtOAc, washed with a saturated aqueous solution of
Na2CO3 followed by brine, then dried over MgSO4. Concentration
under reduced pressure gave crude 2-(3-allyloxyphenyl)ethylurea as a
colorless solid (79 g) which was used in the next step without further
purification. 1H NMR (400 MHz, methanol-d4) δ 7.97 (s, 1H), 7.22−
7.13 (m, 1H), 6.84−6.71 (m, 3H), 6.13−5.97 (m, 1H), 5.39 (dq, J =
17.3, 1.7 Hz, 1H), 5.23 (dq, J = 10.6, 1.6 Hz, 1H), 4.52 (ddt, J = 5.1,
3.5, 1.6 Hz, 2H), 3.34 (d, J = 7.0 Hz, 2H), 2.98 (d, J = 0.6 Hz, 2H),
2.74 (t, J = 7.3 Hz, 2H). LCMS: m/z 221 [M + H]+.
1-[2-(3-Allyloxyphenyl)ethyl]hexahydropyrimidine-2,4,6-
trione. To a stirred solution of sodium (16 g, 718.0 mmol) in EtOH
(1.0 L), diethyl malonate (109.1 mL, 718.0 mmol) was added, and
the reaction mixture was heated under reflux for 1 h. Crude 2-(3-
allyloxyphenyl)ethylurea (72 g, 359.0 mmol) in EtOH (200 mL) was
added, and the reaction mixture was heated under reflux for 12 h. The
reaction was cooled to RT, 1 M aq HCl was added, and the
precipitate obtained was filtered off, washed with water, and dried
under vacuum to give 1-[2-(3-a l ly loxyphenyl)ethy l] -
hexahydropyrimidine-2,4,6-trione as a yellow solid (82 g, 79%
yield). 1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.25−7.16 (m,
1H), 6.87−6.72 (m, 3H), 6.05 (ddt, J = 17.3, 10.5, 5.3 Hz, 1H), 5.41
(dq, J = 17.3, 1.6 Hz, 1H), 5.28 (dq, J = 10.5, 1.4 Hz, 1H), 4.53 (dt, J
= 5.3, 1.5 Hz, 2H), 4.15−4.04 (m, 2H), 3.61 (s, 2H), 2.92−2.82 (m,
2H). LCMS: m/z 289 [M + H]+.
9-Allyloxy-2-chloro-6,7-dihydropyrimido[6,1-a]isoquinolin-
4-one. A so lu t ion of 1-[2 -(3 -a l ly loxypheny l)e thy l ] -
hexahydropyrimidine-2,4,6-trione (50 g, 173.4 mmol) in POCl3
(100 mL) was stirred at 50 °C for 3 days. POCl3 was concentrated
under pressure, and the residue was dissolved in dichloromethane
(DCM) and quenched with a saturated aqueous solution of NaHCO3.
The organic layer was washed with water, dried over MgSO4, filtered,
and concentrated under reduced pressure to give crude 9-allyloxy-2-
chloro-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one as a yellow solid
(46 g, 92% yield). 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.8 Hz,
1H), 6.94 (dd, J = 8.8, 2.6 Hz, 1H), 6.85−6.80 (m, 1H), 6.67 (s, 1H),
6.04 (ddt, J = 17.2, 10.5, 5.2 Hz, 1H), 5.43 (dq, J = 17.3, 1.6 Hz, 1H),
5.34 (dq, J = 10.5, 1.4 Hz, 1H), 4.62 (dt, J = 5.3, 1.5 Hz, 2H), 4.26−
4.19 (m, 2H), 3.01 (t, J = 6.7 Hz, 2H). LCMS: m/z 289 [M + H]+.
9-Al lyloxy-2-[ [ (2S ) -1 ,4-dioxan-2-yl ]methoxy]-6,7-
dihydropyrimido[6,1-a]isoquinolin-4-one. To a solution of (R)-
2-hydroxymethyl[1,4]dioxane (1.82 g, 15.4 mmol) in anhydrous
DCM (100 mL) under N2 at 0 °C, NaH (618 mg, 15.4 mmol, 60% in
mineral oil) was added and stirred for 15 min. 9-Allyloxy-2-chloro-6,7-
dihydropyrimido[6,1-a]isoquinolin-4-one (3.43 g, 11.9 mmol) was
added, and the reaction mixture was stirred and warmed up to RT
overnight. Saturated NH4Cl was added, and the organic layer was
washed with water, dried over MgSO4, and concentrated under
reduced pressure. The crude product was purified by flash
chromatography on silica gel eluting with 5% MeOH in DCM to
afford 9-al ly loxy-2-[[(2S)-1,4-dioxan-2-yl]methoxy]-6,7-
dihydropyrimido[6,1-a]isoquinolin-4-one as a yellow solid (2.90 g,
66% yield). 1H NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 8.7 Hz,
1H), 7.02−6.93 (m, 2H), 6.54 (s, 1H), 6.06 (ddt, J = 17.3, 10.5, 5.2
Hz, 1H), 5.42 (dq, J = 17.3, 1.7 Hz, 1H), 5.29 (dq, J = 10.6, 1.5 Hz,
1H), 4.67 (dt, J = 5.3, 1.5 Hz, 2H), 4.30−4.20 (m, 2H), 4.06−3.98
(m, 2H), 3.85 (dddd, J = 10.0, 5.9, 4.4, 2.6 Hz, 1H), 3.78 (td, J = 10.7,
10.1, 2.8 Hz, 2H), 3.70−3.56 (m, 2H), 3.49 (td, J = 10.8, 2.7 Hz, 1H),
3.38 (dd, J = 11.4, 9.9 Hz, 1H), 2.97 (t, J = 6.5 Hz, 2H). LCMS: m/z
371 [M + H]+.
2-[[ (2S ) -1,4-Dioxan-2-yl]methoxy]-9-hydroxy-6,7-
dihydropyrimido[6,1-a]isoquinolin-4-one. To a suspension of 9-
allyloxy-2-[[(2S)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-
a]isoquinolin-4-one (31.2 g, 84.2 mmol) in a mixture of DCM/
MeOH (300 mL/300 mL), K2CO3 (23.27 g, 168.4 mmol) and
Pd(PPh3)4 (4.86 g, 4.21 mmol) were added, and the reaction mixture
was degassed before stirring at RT overnight. After completion, the
reaction was quenched with H2O, the aqueous layer was separated,
and the pH was adjusted to pH 1 with 2 M aq HCl, and the
precipitate formed was filtered off, washed with water, and dried to
afford 2-[[(2S)-1,4-dioxan-2-yl]methoxy]-9-hydroxy-6,7-
dihydropyrimido[6,1-a]isoquinolin-4-one as a yellow solid (18.62 g,
67% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 7.83 (d,
J = 8.6 Hz, 1H), 6.77 (dd, J = 8.6, 2.5 Hz, 1H), 6.74 (d, J = 2.4 Hz,
1H), 6.44 (s, 1H), 4.28−4.18 (m, 2H), 4.03−3.94 (m, 2H), 3.89−
3.72 (m, 3H), 3.69−3.56 (m, 2H), 3.49 (td, J = 10.8, 2.7 Hz, 1H),
3.37 (dd, J = 11.4, 9.9 Hz, 1H), 2.91 (t, J = 6.5 Hz, 2H). LCMS: m/z
331 [M + H]+.
[ 2 - [ [ ( 2S ) - 1 , 4 -D ioxan -2 - y l ]me thoxy ] - 4 -oxo -6 , 7 -
dihydropyrimido[6,1-a]isoquinolin-9-yl] Trifluoromethanesul-
fonate. A solution of 2-[[(2S)-1,4-dioxan-2-yl]methoxy]-9-hydroxy-
6,7-dihydropyrimido[6,1-a]isoquinolin-4-one (23.25 g, 70.5 mmol),
N-phenyl-bis(trifluoromethanesulfonimide) (27.69 g, 77.5 mmol),
and Et3N (17.5 mL, 126.8 mmol) in DCM (800 mL) under N2 was
stirred at RT for 5 h. The reaction mixture was concentrated, and the
crude product was purified by recrystallization from iPrOH to afford
Table 9. Pharmacokinetic Parameters of 36 at Steady State
in Female BALB/c Mice after Multiple Oral Doses of 3 or
10 mg kg−1 day−1 a
3 mg kg−1 day−1
(n = 2 or 3)
10 mg kg−1 day−1
(n = 2 or 3)
Cmax (ng/mL) 1837 8140
Cmax/dose 612 814
Tmax (h) 1 1
AUC(0−24h) (ng·h/mL) 5556 50387
AUC(0−24h)/dose 1852 5039
t1/2 (h) 2.9 2.3
aAbbreviations: AUC, area under curve; Cmax, maximum plasma
concentration; Tmax, time to Cmax; t1/2, half-life.
Scheme 1. Synthesis of (S)-GLPG1205 (36)a
aReagents and conditions: (a) urea, AcOH, conc HCl, water, reflux; (b) conc HBr, reflux; (c) AllylBr, K2CO3, DMF; (d) Na, EtOH, diethyl
malonate, reflux; (e) POCl3, 50 °C; (f) [(2R)-1,4-dioxan-2-yl]methanol, tBuOK, DCM; (g) Pd(PPh3)4, K2CO3, MeOH/THF; (h)
PhN(SO3CF3)2, Et3N, DCM; (i) ethynylcyclopropane, Pd(PPh3)4, CuI, Et3N, DMF.
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[2-[[(2S)-1,4-dioxan-2-yl]methoxy]-4-oxo-6,7-dihydropyrimido[6,1-
a]isoquinolin-9-yl] trifluoromethanesulfonate as a white solid (24.5 g,
75% yield). 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.7 Hz, 1H),
7.31 (dd, J = 8.7, 2.6 Hz, 1H), 7.27−7.23 (m, 1H), 6.37 (s, 1H),
4.50−4.35 (m, 2H), 4.24 (dd, J = 7.1, 5.8 Hz, 2H), 4.02−3.93 (m,
1H), 3.90−3.69 (m, 4H), 3.65 (ddd, J = 11.7, 10.6, 3.0 Hz, 1H), 3.48




To a solution of [2-[[(2S)-1,4-dioxan-2-yl]methoxy]-4-oxo-6,7-
dihydropyrimido[6,1-a]isoquinolin-9-yl] trifluoromethanesulfonate
(42 g, 90.8 mmol) in anhydrous DMF (840 mL), cyclopropylacety-
lene (15.38 mL, 181.6 mmol) was added followed by Et3N (31.5 mL,
227.0 mmol), and the mixture was degassed. Pd(PPh3)2Cl2 (3.19g,
4.5 mmol) was added with CuI (3.46 g, 18.2 mmol), and the reaction
mixture was heated at 50 °C overnight. The reaction mixture was
concentrated and the crude was purified by flash chromatography on
silica gel eluting with 1−3% MeOH in DCM to afford 9-(2-
cyclopropylethynyl)-2-[[(2S)-1,4-dioxan-2-yl]methoxy]-6,7-
dihydropyrimido[6,1-a]isoquinolin-4-one as a light brown solid (30.2
g, 88% yield). 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 8.2 Hz,
1H), 7.32 (dd, J = 8.2, 1.6 Hz, 1H), 6.31 (s, 1H), 4.45−4.32 (m, 2H),
4.16 (dd, J = 7.0, 5.9 Hz, 2H), 4.00−3.90 (m, 1H), 3.87−3.57 (m,
5H), 3.45 (dd, J = 11.5, 10.1 Hz, 1H), 2.93 (t, J = 6.5 Hz, 2H), 1.45
(tt, J = 8.2, 5.0 Hz, 1H), 0.94−0.85 (m, 2H), 0.85−0.75 (m, 2H).
LCMS: 0.70 min, m/z 379.5 [M + H]+. Chromatographic conditions:
Waters Alliance HPLC, column Daicel Chiralpak (Chiral Technol-
ogies, West Chester, PA, USA) IG 4.6 mm i.d. × 250 mm, 5 μm
particle size, wavelength 330 nm, flow rate 0.8 mL/min, column
temperature 25 °C, injection volume 10 μL, run time 65 min, isocratic
elution (85/15) tert-butyl methyl ether/ethanol, retention time 32.87
min.
Biology. HTS. The cAMP assay measures the level of Gi protein
activation following agonist occupancy of GPR84, in the presence of
forskolin to stimulate production of cAMP, and adenylate cyclase and
3-isobutyl-1-methylxanthine (IBMX) to block phosphodiesterase
activity. HEK293T samples stably transfected with recombinant
human GPR84 (Multiscreen; Multispan, Hayward, CA, USA) were
seeded at a density of 2500 cells/well in a 384-well plate in suspension
on the day of the assay in assay buffer (1× Hanks’ balanced salt
solution [HBSS]), 20 mM (4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES), 0.5 mM IBMX). GPR84 was stimulated with
capric acid as the natural ligand at EC85 (30.5 μM), and tested
compounds were added simultaneously for 30 min before the addition
of 1.5 μM forskolin for 30 min. Cells were lysed and analyzed for
cAMP level using a competitive immunoassay in homogeneous time-
resolved fluorescence (HTRF) format (Cisbio, Bedford, MA, USA).
Fluorescence signals were read on a PerkinElmer ViewLux1430
microplate imager (PerkinElmer, Boston, MA, USA).
Recombinant Human GPR84 GTPγS Binding Assay. The
assay was performed in a 96-well plate where the following reagents
were added. First, 50 μL of hit compound from HTS was added into
the assay plate, followed by addition of 20 μL of DIM at EC80
concentration (concentration which gives 80% of the activity of
GPR84) and was incubated with 30 μL of mixture consisting of
membranes derived from stable cell line overexpressing recombinant
human GPR84, [35S]GTPγS, and scintillation proximity assay (SPA)
beads (PerkinElmer, Boston, MA, USA; RPNQ0001). All compo-
nents were diluted in assay buffer containing 20 mM HEPES, pH 7.4;
5 mM MgCl2; 250 mM NaCl; 0.05% bovine serum albumin (BSA);
75 μg/mL saponin. Reactions were incubated at room temperature
for 90 min followed by centrifugation. Plates were read on a Topcount
reader (Molecular Devices, Sunnyvale, CA, USA) immediately after
centrifugation.
IP1 Assay. The IP1 assay using transiently transfected cells
allowed the development of similar assays with overexpression of
either mouse or human GPR84. IP1 activity was measured in
HEK293T cells transiently transfected with a variant of Gq protein
(GNAO1 transcription variant 1) and GPR84 using the Cisbio IP-
One assay, which detected the accumulation of IP1, a stable
downstream metabolite of IP3 induced by activation of a
phospholipase C (PLC) cascade.
HEK293T cells were transiently transfected in suspension with a
variant of Gq protein and recombinant mouse or human GPR84 using
Jet-PEI (Polyplus-transfection, Sebastien Brant, France) and seeded at
a density of 25 000 cells/well in a 384-well plate. After overnight
incubation, the transfection mix was removed and replaced by cell
culture medium for 24 h. The cells were then treated with test
compounds for 30 min before addition of capric acid at EC80 for 1 h
for the human assay. As transfection of mouse GPR84 resulted in IP1
activity in the absence of capric acid stimulation, compounds were
tested in inverse agonist mode without addition of capric acid. IP1
was measured using competitive immunoassay in HTRF format
(Cisbio, Bedford, CA, USA) according to manufacturer’s instructions.
Fluorescence signal was read on PerkinElmer EnVision (PerkinElmer,
Boston, MA, USA).
PDE4A Inhibition. The IC50 value for human PDE4A was
determined in a HTRF based cAMP assay. PDE4A present in a
HEK293 cell lysate containing overexpressed PDE4A hydrolyzes
cAMP into 5′AMP. The amount of cAMP present is measured in a
competitive immunoassay, which is based on competition between
native cAMP and d2-labeled cAMP for binding to an anti-cAMP
monoclonal antibody labeled with cryptate. The specific signal (i.e.,
energy transfer) is inversely proportional to the concentration of
cAMP.
Human Neutrophil Migration. Freshly isolated human
neutrophils were diluted in a suspension of 8.9 × 106 cells per mL.
20 μL of compound solution in chemotaxis buffer was added to the
180 μL cell suspension. The mixture was incubated at 37 °C for 30
min with intermediate resuspension of the cells after 15 min.
Following this, 70 μL of cell suspension was transferred to the upper
compartment of a Corning HTS Transwell 96 permeable support
system with 5.0 μm pore size polycarbonate membrane (Corning,
Corning, NY, USA; catalog no. 3387). The receiver well of the
Transwell system was then filled with 200 μL of chemotaxis buffer
containing compound and chemotactic agent (embelin). After
incubation at 37 °C in 5% CO2 for 1 h, the upper plate of the
Transwell system was removed and the cell suspension in the receiver
plate is transferred to a 96-well V-bottom plate. 50 μL of DPBS was
added to the receiver plate to prevent remaining cells from drying out.
The V-bottom plate was centrifuged for 6 min at 1500 rpm. The
supernatant was removed, and the cells were resuspended in 50 μL
DPBS. The cells were then transferred back to the receiver plate of the
Transwell system. After this, 100 μL of ATPlite solution
(PerkinElmer, Boston, MA, USA; catalog no. 436110) was added to
the cells. The plate was incubated for 10 min in the dark while
shaking. 170 μL of cell lysate was then transferred to a white 96-well
plate, and luminescence was measured. The detected luminescent
signal was considered as linearly related to the number of cells having
migrated from the upper well to the receiver well.
Rat Neutrophil Migration. Freshly isolated rat neutrophils were
diluted in a suspension of 8.9 × 106 cells per mL. 10 μL of compound
solution in chemotaxis buffer was added to the 90 μL cell suspension.
The mixture was incubated at 37 °C for 30 min with intermediate
resuspension of the cells after 15 min. Following this, 75 μL of cell
suspension was transferred to the upper compartment of a Corning
HTS Transwell 96 permeable support system with 5.0 μm pore size
polycarbonate membrane (Corning, Corning, NY, USA; catalog no.
3387). The receiver well of the Transwell system was then filled with
200 μL of chemotaxis buffer containing compound and chemotactic
agent (embelin). After incubation at 37 °C in 5% CO2 for 1 h, the
upper plate of the Transwell system was removed and 70 μL of
CellTiter-Glo substrate (Promega, Madison, WI, USA; catalog no.
G755B) was added to a 96-well V-bottom plate. The plate was
incubated for 10 min in the dark while shaking. 180 μL of cell lysate
was then transferred to a white 96-well plate, and luminescence was
measured. The detected luminescent signal was considered as
linearely related to the number of cells having migrated from the
upper well to the receiver well.
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Liver Microsomal Stability (LMS) Assay. The microsomal
stability assay was performed by incubation of test compound at 1
μM, 0.2% DMSO in phosphate buffer with microsomes (0.5 mg/mL)
from mouse, rat, dog, or human (Xeno-Tech, Kansas City, KS, USA),
and cofactors with final concentrations of 0.6 U/mL glucose-6-
phosphate dehydrogenase, 3.3 mM MgCl2, 3.3 mM glucose-6-
phosphate, and 1.3 mM nicotinamide adenine dinucleotide phosphate
(NADP)+. Before addition of the microsomes (time zero) and after
30 min of incubation at 37 °C with shaking, the reaction was stopped
and proteins were precipitated with an excess of acetonitrile
containing an internal standard. The samples were mixed, centrifuged,
and filtered, and the supernatant was analyzed by liquid chromatog-
raphy−mass spectrometry/mass spectrometry (LC−MS/MS). The
instrument responses (peak areas/IS peak area) were referenced to
the zero-time point samples (considered as 100%) in order to
determine the percentage of compound remaining. Verapamil (1 μM)
and warfarin (1 μM) were used as reference compounds, as unstable
and stable compounds, respectively.
In vitro scaled intrinsic clearance (CLint scaled) was calculated from
the half-life using the following equations:
(1) Intrinsic clearance equation:
[μ ] =
[ ]
× [μ ]− −
t







(2) Scaled intrinsic clearance equation:
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Hepatocyte Stability Assay. The hepatocyte stability assay was
performed by incubation of test compound at 1 μM, 0.03% DMSO in
modified Krebs−Henseleit buffer with suspension of pooled
cryopreserved hepatocytes (BioIVT, Hicksville, NY, USA) from
mouse, rat, dog, or human (BioIVT, Hicksville, NY, USA) at 0.5
million viable hepatocytes/mL.
Before adding the hepatocytes (time zero) and after 10, 20, 45, 90,
120, and 180 min of incubation (n = 2) at 37 °C while gently shaking,
the reaction was stopped and proteins were precipitated with an
excess of acetonitrile containing an internal standard. The samples
were mixed, centrifuged, and filtered, and the supernatant was
analyzed by liquid chromatography−mass spectrometry/mass spec-
trometry (LC−MS/MS). The instrument responses (peak areas/IS
peak area) were referenced to the zero-time point samples
(considered as 100%) in order to determine the percentage of
compound remaining. Testosterone (1 μM) and 7-hydroxycoumarin
(1 μM) were used as phase I and phase II reaction controls, while
caffeine was used as a negative control.
In vitro intrinsic clearance (CLint) was calculated from half-life
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Plasma Protein Binding Assay. Plasma protein binding was
determined by equilibrium dialysis using the Pierce Red device plate
with inserts (Thermo Fisher Scientific, Waltham, MA, USA). Test
compound at 5 μM (0.5% DMSO) spiked in freshly thawed human,
rat, mouse, or dog plasma (Bioreclamation INC, Westbury, NY, USA)
was dialyzed against phosphate-buffered saline (PBS, pH 7.4) at 37
°C under shaking for 4 h. Proteins were precipitated with an excess of
methanol, and samples were mixed and centrifuged, and the
supernatant was analyzed by liquid chromatography−mass spectrom-
etry/mass spectrometry (LC−MS/MS). Addition of compound peak
areas in the buffer chamber and the plasma chamber was considered
to be 100% compound. The percentage bound to plasma proteins was




peak area of plasma peak area of buffer
peak area of plasma
Acebutolol and nicardipine are included in the assay design as low and
high binding controls.
Intestinal Permeability on Caco-2 Cells. Caco-2 cells were
obtained from European Collection of Cell Cultures (ECACC) and
used after a 21-day cell culture in 24-well Transwell plates.
GLPG1205 and the references (vinblastine and propranolol) were
prepared in protein-free Hanks’ balanced salt solution containing 25
mM HEPES (pH 7.4) at a concentration of 10 μM and added to
either the apical or basolateral chambers of a Transwell plate
assembly.
Before the experiment, the integrity of the monolayer was checked
by measuring the transepithelial resistance. Lucifer yellow (LY) was
added to the donor buffer in all wells to assess integrity of the cell
layers by monitoring LY permeation. As LY cannot freely permeate
lipophilic barriers, a high degree of LY transport indicates poor
integrity of the cell layer.
After a 1 h incubation at 37 °C, aliquots were taken from both
apical (A) and basolateral (B) chambers and added to acetonitrile
containing analytical internal standard (carbamazepine) in a 96-well
plate. Concentrations of compound in the samples were measured by
LC−MS/MS.
Apparent permeability (Papp) values were calculated from the
relationship
=





compound /( compound )
/(surface area 60 10 cm/s)
app
acceptor final acceptor donor initial donor
inc donor
6
where Vdonor is the volume of the apical chamber at 125 μL, Vacceptor is
the volume of the basolateral chamber at 600 μL, Tinc is the
incubation time of 3600 s, and the surface area for the 24-well
Transwell is 0.33 cm2. The efflux ratios, as an indication of active
efflux from the apical cell surface, were calculated using the ratio of
Papp(B → A)/Papp(A → B).
CYP Direct Inhibition Assay. A 5 mM stock solution of
compound was prepared in methanol. This stock was serially diluted
1:3 in methanol and then added in duplicates to a mixture containing
50 mM potassium phosphate buffer, pH 7.4, and human liver
microsomes (BD Gentest, BD, Wokingham, U.K.). A total of seven
different concentrations (0.14−100 μM in final reaction mixture; 2%
methanol) of compound were prepared in duplicates.
After prewarming for 5 min at 37 °C, the 20 min preincubation was
started by adding a probe substrate to the first concentration range
(first replica) and a cofactor mix (7. 65 mg/mL glucose-6-phosphate,
1.7 mg/mL NADP, 6 U/mL of glucose-6-phosphate dehydrogenase)
to the second replica. Final concentrations of cofactor mix
components were as follows: 1.56 mg/mL glucose-6-phosphate,
0.34 mg/mL NADP, 1.2 U/mL of glucose-6-phosphate dehydrogen-
ase.
After preincubation, the reaction was finally started by adding the
cofactor mix to the first replica and adding the probe substrate to
second replica (opposite from preincubation).
After incubation at 37 °C, the reaction (aliquot of 50 μL) was
terminated with 150 μL of acetonitrile/methanol (2:1) solution with
internal standard (diclofenac). Samples were centrifuged and the
supernatant fractions analyzed by LC−MS/MS.
The instrument responses (ratio of compound and internal
standard peak areas) were referenced to those for solvent controls
(assumed as 100%) in order to determine the percentage reduction in
probe metabolism.
Percent of control activity versus concentration plots were
generated and fitted using GraphPad Prism software to determine
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IC50 for both substrate- and cofactor preincubations, as well as the
IC50 fold shift.
hERG Manual Patch Clamp Assay. Whole-cell patch-clamp
recordings were performed using an EPC10 amplifier controlled by
Pulse version 8.77 software (HEKA, Ludwigshafen, Germany). The
external bathing solution contained 135 mM NaCl, 5 mM KCl, 1.8
mM CaCl2, 5 mM glucose, 10 mM HEPES, pH 7.4. The internal
patch pipet solution contained 100 mM K gluconate, 20 mM KCl, 1
mM CaCl2, 1 mM MgCl2, 5 mM Na2ATP, 2 mM glutathione, 11 mM
ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid
(EGTA), 10 mM HEPES, pH 7.2. Compound was perfused using
an automate scientific pressurized superfusion system coupled to a
Biologic micromanifold.
All recordings were performed on HEK293 cells stably expressing
hERG channels. Cells were cultured on 12 mm round coverslips
(German glass; Bellco, Vineland, NJ, USA) anchored in the recording
chamber using two platinum rods (Goodfellow, Coraopolis, PA,
USA). hERG currents were evoked using an activating pulse to +40
mV for 1000 ms followed by a tail current pulse to −50 mV for 2000
ms, and holding potential was −80 mV. Pulses were applied every 15
s, and all experiments were performed at room temperature. For the
concentration response, peak tail current amplitude was measured
during the voltage step to −50 mV.
PK Mouse. This study was performed with 42 naiv̈e male CD1
mice, weighing 18−20 g upon arrival (4−5 weeks old). The first
group of mice were dosed iv via a bolus in the tail vein with a dose
level of 1 mg/kg, and the second group of mice was dosed orally as a
single esophageal gavage with a dose level of 5 mg/kg.
Formulations were prepared the day before administration and kept
at room temperature, protected from light. For the iv route,
compound was formulated in PEG 200 and saline (60/40; v/v) as
a clear solution. For the oral route, compound was formulated in PEG
200/purified water (60/40; v/v) as a homogeneous suspension.
Before the oral dosing, the animals were deprived of food for at least
12 h before compound administration and 4 h after administration.
All animals had free access to tap water.
From all animals, approximately 500 μL blood samples were
collected by intracardiac puncture and placed into tubes containing
Li-heparin as anticoagulant. Blood samples were collected at the
following time points: iv, 0.05, 0.25, 0.5, 1, 3, 5, and 8 h after dosing
(n = 3 mice per sampling time); po, 0.25, 0.5, 1, 3, 5, 8, and 24 h after
dosing (n = 3 mice per sampling time). Each mouse was sampled
once and then euthanized.
Blood was kept on ice. Within 1 h after sampling, blood was
centrifuged at 5000 rpm for 10 min at 4 °C. Immediately after
centrifugation, the resulting plasma samples were collected into
polypropylene tubes and were kept frozen at −20 °C pending
bioanalysis.
Plasma samples were assayed by LC−MS/MS with a non-good-
laboratory-practice (non-GLP)-validated method. Compound 36
plasma concentrations were calculated against a calibration curve
consisting of eight levels with a 3 log amplitude. Back-calculated
values for quality control (three levels prepared in duplicate) were
used for accepting or rejecting the entire batch. The lower limit of
quantification was 4 ng/mL with a plasma volume of 25 μL.
Plasma proteins were precipitated with an excess of methanol
containing the internal standard, and the corresponding supernatant
was injected onto a C18 column. Analytes were eluted out of the
HPLC system by increasing the percentage of the organic mobile
phase. An API5500 QTrap mass spectrometer (AB Sciex, Sciex,
Warrington, U.K.) was used for the simultaneous detection and
quantification of 36.
PK parameters were calculated from the mean of individual plasma
concentrations by noncompartmental analysis using WinNonlin
software (Pharsight, version 5.2; Certara, Princeton, NJ, USA).
PK Rat. This study was performed with six naiv̈e male Sprague
Dawley rats, weighing 180−200 g upon arrival (6−8 weeks old).
Catheterized rats (in the jugular vein) were used to avoid
interindividual variability. Three rats per group was a sufficient
number to carry out statistical calculations.
For the iv route, compound was formulated in PEG 200 and NaCl
for injection (60/40; v/v) as a clear solution. For the oral route,
compound was formulated in PEG 200 and purified water (60/40; v/
v) as a clear solution.
Rats (n = 3) were dosed iv via a bolus in the tail vein. Three
additional rats were dosed orally as a single gavage. The iv bolus and
the oral administration were given with a dose volume of 5 mL/kg.
Actual dose volumes were based on the individual body weights.
From all animals, approximately 200 μL blood samples were
collected via a catheter into the jugular vein and placed into tubes
containing Li-heparin as anticoagulant. Blood samples were collected
at the following time points: iv, 0.05, 0.25, 0.5, 1, 3, 5, 8, and 24 h
after dosing; po, 0.25, 0.5, 1, 3, 5, 8, and 24 h after dosing. Each rat
was sampled seven or eight times (at each sampling time), depending
on the route of administration. Just after each sampling, the same
volume of physiological serum with sodium heparin (50 UI/mL) was
injected into the catheter to avoid blocking.
Blood was kept on ice. Within 1 h after sampling, blood was
centrifuged at 5000 rpm for 10 min at 4 °C. Immediately after
centrifugation, the resulting plasma samples were collected into
polypropylene tubes and were kept frozen at −20 °C pending
bioanalysis.
Plasma samples were assayed by LC−MS/MS with a non-GLP-
validated method. Plasma concentrations were calculated against a
calibration curve consisting of eight levels with a 3 log amplitude.
Back-calculated values for quality control (three levels prepared in
duplicate) were used for accepting or rejecting the whole batch.
Plasma proteins were precipitated with an excess of methanol
containing the internal standard, and the corresponding supernatant
was injected on a C18 column. Analytes were eluted out the HPLC
system by increasing the percentage of the organic mobile phase. An
API5500 QTrap mass spectrometer (ABSciex, Sciex, Warrington,
U.K.) was used.
PK parameters were calculated for each individual rat by
noncompartmental analysis using WinNonlin software (Pharsight,
version 5.2; Certara, Princeton, NJ, USA).
PK Dog. This study was performed with three non-naiv̈e male
Beagle dogs. Formulations were prepared the day of administration.
Dogs (n = 3) were dosed iv via a 10 min infusion via a catheter with
a dose level of 0.5 mg/kg (12 mL kg−1 h−1). After a washout of 3 days,
they were dosed orally as a single gavage with a dose level of 2.5 mg/
kg in PEG200/water. The oral dose of 2.5 mg/kg was given with a
dose volume of 5 mL/kg. Actual dose volumes were based on the
individual body weights. Approximately 250 g of Harlan Teklad 2027
diet was distributed daily to each animal. The food was given 4 h after
the iv administration. Before administration by the po route, animals
were fasted for a period of at least 12 h before treatment, and food
was given just after the 4 h blood sampling. All animals had free access
to tap water.
From all animals approximately 0.5 mL blood samples were taken
without anesthetic from a jugular or cephalic vein into tubes
containing lithium heparin as anticoagulant. Blood samples were
collected at the following time points: iv, at predose, 0.083, 0.167
(end of infusion), 0.5, 1, 2, 4, 6, 8, 10, and 24 h after start of infusion;
po, at predose and then 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, and 24 h after
dose administration.
Plasma samples were assayed by LC−MS/MS with a non-GLP-
validated method. Compound 36 plasma concentrations were
calculated against a calibration curve consisting of eight levels with
a 3 log amplitude. Back-calculated values of the quality control
samples (three levels prepared in duplicate) were used for accepting
or rejecting the whole batch. The lower limit of quantification was 4
ng/mL with a plasma volume of 25 μL.
Plasma proteins were precipitated with an excess of methanol
containing the internal standard, and the corresponding supernatant
was injected on a C18 column. Analytes were eluted out the high-
performance liquid chromatography (HPLC) system by increasing
the percentage of the organic mobile phase. An API5500 QTrap mass
spectrometer (ABSciex, Sciex, Warrington, U.K.) was used for the
detection and quantification of 36.
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PK parameters were calculated for each individual dog by
noncompartmental analysis using WinNonlin software (Pharsight,
version 5.2; Certara, Princeton, NJ, USA).
Negative Allosteric Modulation of Known GPR84 Agonists
by GLPG1205. Membrane Preparation. Membranes were
generated from Flp-In T-REx 293 cells treated with 100 ng/mL
doxycycline to induce expression of FLAG-GPR84-Gαi2.32 Cells were
washed with ice-cold phosphate buffered saline, removed from dishes
by scraping, and centrifuged at 3000 rpm for 5 min at 4 °C. Pellets
were resuspended in TE buffer (10 mM Tris-HCl, 0.1 mM EDTA;
pH 7.5) containing a protease inhibitor mixture (Roche Applied
Science, West Sussex, U.K.) and homogenized with a 5 mL hand-held
homogenizer. This material was centrifuged at 1500 rpm for 5 min at
4 °C, and the supernatant was further centrifuged at 50 000 rpm for
30 min at 4 °C. The resulting pellet was resuspended in TE buffer,
and protein content was assessed using a BCA protein assay kit
(Pierce, Fisher Scientific, Loughborough, U.K.).
Competition Binding Assay. Assays were performed using 0.2
nM [3H]38, binding buffer (phosphate-buffered saline with 0.5% fatty
acid free bovine serum albumin; pH 7.4) and the indicated
concentrations of test compounds, in a total assay volume of 500
μL. Binding was initiated by the addition of membranes (5 μg of
protein per tube), and incubations were carried out at 25 °C for 1 h.
Reactions were terminated by the addition of ice-cold phosphate
buffered saline and vacuum filtration through GF/C glass filters using
a 24-well Brandel cell harvester (Alpha Biotech, Glasgow, U.K.). Each
reaction tube was washed three times with ice-cold PBS. The filters
were allowed to dry for 2−3 h and then placed in 3 mL of Ultima
Gold XR. Radioactivity was quantified by liquid scintillation
spectrometry.
Reaction Biology Kinase Selectivity Profiling. Inhibition of
152 kinases by 10 μM compound was determined in a Reaction
Biology proprietary nanoliter radioactive HotSpot assay in duplicate.
The principle of the assay consists of the measurement of
incorporated 33P into a specific substrate for each kinase when the
substrate is phosphorylated by the enzyme using [33P]-γ-ATP and
ATP.
Millipore GPCR Profiler Selectivity Profiling. Free intracellular
[Ca2+] flux assays were conducted to test compound agonist and
antagonist activities against 123 GPCRs selected to cover as many
GPCR families as possible. Percentage activation was determined
upon initial addition of compound followed by 10 min incubation at
25 °C (in absence of agonist). Following this initial incubation,
reference agonists were added at EC80 concentration allowing
determination of percentage inhibition of the agonist induced signal
caused by compound.
Dextran Sulfate Sodium (DSS)-Induced Colitis Model. Balb/
cJ female mice (Janvier Labs, Le Genest-Saint-Isle, France) were
housed in a dedicated in house animal facility under specific
pathogen-free conditions according to the Federation for Laboratory
Animal Science Associations guidelines. The study was performed
according to ethical guidelines approved by the Animal Institutional
Care and Use Committee of Galapagos controlled by the French
Authorities (Agreement No. C93-063-06, DDPP, Seine Saint Denis).
Animals were housed in filter top cages, provided with filtered tap
water and standard chow ad libitum, and maintained at 22 ± 2 °C in
55 ± 10% humidity on a 12 h light/dark cycle. The randomization of
mice in the different groups was based on body weight (BW) at study
commencement. A model of chronic colitis was induced in 8-week-old
mice (BW 25 g) with three cycles, each consisting of 4% DSS
administered in drinking water for 4 days, followed by 3 days of
regular drinking water. The mice (n = 10 per group) were orally
administered vehicle (PEG200/H20 [60/40; v/v]) or 1, 3, or 10 mg/
kg of compounds 26, 35, 36 qd from day 1 of DSS administration and
throughout the dosing period. Compound 36 was tested in three
independent experiments. Two positive controls were used in these
different studies: cyclosporine (CsA) at 25 mg/kg qd po in PEG200/
water (60/40; v/v) or sulfazalazine at 20 mg/kg qd po in 0.5%
methylcellulose. Clinical parameters were measured every other day.
DAI (a combined score of body weight loss, stool consistency, and
rectal bleeding scores) was recorded daily. Each criterion was graded
from 0 to 4. Animals were decapitated after brief isoflurane anesthesia.
At necropsy at day 17 of the experiment, the complete colon was
removed and rinsed with sterile PBS. A segment of 5 mm of distal
colon was collected for histology analysis. Histology was performed
on formalin-fixed (4% buffered formaldehyde for 3 h). After fixation,
samples were transferred into a sucrose solution prior to being frozen
in isopentane. Three series of cryosections within a distance of 1 mm
were performed in duplicate. One series of sections were stained with
a Goldner trichrome for colon lesion evaluation, and scoring was
performed. Neutrophil cell infiltration was assayed by immunohis-
tochemistry using anti-Ly6G/Ly6C (clone NIMP-R14, Santa Cruz,
Dallas, TX, USA). Neutrophil identification was followed by manual
quantification of cell number per surface. The neutrophil density was
expressed as a number of cells per mm2 of colon area. Blood was
sampled at day 4 at four time points: 0, 1, 3, and 6 h (and assuming
24 h is equal to the predose sample). Plasma was prepared and 36 was
quantified using LC−MS to assess steady state PK. Statistical analysis
was performed with Prism 5.03 software (GraphPad, San Diego, CA,
USA) with a one-way ANOVA performed on the arcsinh(log)-
transformed neutrophil density data and a two-way ANOVA
performed on the arcsinh(log)-transformed DAI data. Dunnett’s
post-hoc multiplicity correction procedure was applied to the
neutrophil density data, and Bonferonni post-hoc multiplicity
correction procedure was applied to the DAI data.
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■ ABBREVIATIONS USED
ADME, absorption, distribution, metabolism, excretion; ASOL,
aqueous solubility; AUC0−inf, area under the curve (from time
0 to infinity); BEH, ethylene bridged hybrid; BSA, bovine
serum albumin; BW, body weight; cAMP, cyclic adenosine
3′,5′-monophosphate; Cap, capric acid; CAS, Chemical
Abstracts Service; CL, clearance; CLint, intrinsic clearance;
CLunb, unbound clearance; Cmax, maximum plasma concen-
tration; compd, compound; cpm, counts per minute; C0,
concentration extrapolated at time 0 after a bolus intravenous
dose; D, dog; DAI, disease activity index; DIM, 3,3′-
diindolylmethane; DMSO, dimethyl sulfoxide; DSS, dextran
sodium sulfate; ECACC, European Collection of Cell
Cultures; EC50, half maximal effective concentration; EC80,
concentration of agonist leading to 80% maximal response;
EGTA, ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-
tetraacetic acid; ER, efflux ratio; F, oral bioavailability;
GPCR, G-protein-coupled receptor; GTPγS, guanosine 5′-O-
[γ-thio]triphosphate; h, hour; HBSS, Hanks’ balanced salt
solution; hCYP, human cytochrome P450; HEP, hepatocyte;
HEPES, (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;
hERG, human ether-a-̀go-go-related gene; hGPR84, human G-
protein-coupled receptor 84; hGTPγS, human guanosine 5′-O-
[γ-thio]triphosphate; HLM, human liver microsome; HTRF,
homogeneous time-resolved fluorescence; HTS, high-through-
put screen; Hum neutro, human neutrophil migration assay; H,
human; IBD, inflammatory bowel disease; IBMX, 3-isobutyl-1-
methylxanthine; IC50, half maximal inhibitory concentration;
IL, interleukin; IP1, inositol monophosphate; iv, intravenous;
LCMS/MS, liquid chromatography−mass spectrometry/mass
spectrometry; LMS, liver microsomal stability; M, mouse;
MCFA, medium-chain free fatty acid; Me, methyl group;
MED, minimal efficacious dose; MELK, maternal embryonic
leucine zipper kinase; MIC, microsomal; min, minute; mRNA,
messenger ribonucleic acid; MW, molecular weight; NMR,
nuclear magnetic resonance; OBD, optical bed density; Papp
A2B, apparent permeability from apical to basal chambers;
PDA, photodiode array; PDE4A, phosphodiesterase 4; PEG,
polyethylene glycol; PK, pharmacokinetics; PPB, plasma
protein binding; po, per os; POCl3, phosphoryl chloride;
PSA, polar surface area; qd, once daily; R, rat; rpm, revolutions
per minute; RT, room temperature; SAR, structure−activity
relationship; SPA, scintillation proximity assay; SQD, single
quadrupole detection; T1/2, half-life; Tmax, time at maximum
plasma concentration; TNF-α, tumor necrosis factor α; UPLC,
ultraperformance liquid chromatography; UV, ultraviolet; Vss,
apparent volume of distribution at steady state
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